Prostate-specific membrane antigen (PSMA)-PET is already a standard imaging tool in prostate cancer treatment. Now, a phase 3 clinical trial suggests the imaging modality may also help determine which ...

Recognition places Lumea among elite global winners including Medtronic and Thermo Fisher Scientific in one of digital health’s most competitive annual programs ...

“As announced this morning, we delivered a strong first quarter. We reported record first quarter total revenue for the company of $17.8 million, led by record first quarter Focal One Robotic HIFU ...

Memorial Healthcare System in Broward County, Fl has micro-ultrasound tech to help prostate cancer detection with more precise imaging and targeted biopsies. The micro-ultrasound allows us to continue ...

Percutaneous liver mass biopsies, including coaxial needle biopsy (CNB), have become the preferred method for obtaining tissue samples in diagnosing or characterizing liver masses. Despite the advent ...

Adam B. Weiner, MD, sits down with Giancarlo Marra, MD, at EAU 2026 to discuss transperineal vs transrectal biopsy for prostate cancer diagnosis. Mara highlights findings from a contemporary ...

An imaging test could safely halve the number of people who need a biopsy for suspected prostate cancer following inconclusive or reassuring results from an MRI scan, new research has found. Findings ...

Role of urinary exosomal FAM153C-RPL19 in detection and risk stratification of prostate cancer: A multicentre Chinese cohort study. This is an ASCO Meeting Abstract from the 2026 ASCO Genitourinary ...

Prostate-specific antigen (PSA) is a widely used biomarker for prostate cancer (PCa), but its limitations are evident in patients with PSA at boundary level. We present a 61-year-old male with gross ...